On May 29，2026，the Center for Drug Evaluation of the National Medical Products Administration publicly solicited comments on the Technical Guidelines for Bioequivalence Studies of Iron Sucrose Injection（Draft for Comments）. Although this document falls within the scope of pharmaceutical registration regulation，because it is directly related to export market access and quality consistency requirements for intravenous iron supplements relied upon in integrated cultural tourism and medical scenarios such as plateau tourism，elderly wellness care，and plateau sickness prevention，it will have a substantive impact on supply chain entities providing supporting pharmaceutical products to overseas health tourism institutions，cross-border medical travel agencies，and international wellness destination operators.

Event Overview

On May 29，2026，the Center for Drug Evaluation（CDE）of the National Medical Products Administration released the Technical Guidelines for Bioequivalence Studies of Iron Sucrose Injection（Draft for Comments）on its official website，soliciting public comments. The document clarifies the technical pathway，trial design，evaluation criteria，and quality comparability requirements for conducting bioequivalence（BE）studies on iron sucrose injection，and applies to generic drug applications and supportive studies for overseas registration of marketed products. At the current stage，it is a draft for comments and has not yet become an official technical guideline.

Which Segmented Industries Will Be Affected

Pharmaceutical exporters serving overseas health tourism markets：Iron sucrose injection is commonly used in scenarios such as intervention for acute iron-deficiency anemia among tourists in high-altitude areas and chronic anemia management for elderly wellness travel groups. It is a routinely stocked intravenous iron supplement for partner medical institutions at some international wellness destinations（such as routes along the Qinghai-Tibet line and wellness bases on the Yunnan-Guizhou Plateau）. This guideline will directly affect the completeness of registration application materials and the compliance of clinical evaluation for products supplied to overseas health tourism purchasers（such as cross-border medical travel agencies and overseas wellness operation platforms）.

CDMO/CMO enterprises undertaking international registration services：Enterprises providing contract manufacturing or registration support services for iron sucrose injection to overseas clients need to adjust BE trial protocol design，analytical method validation，and quality comparison study strategies in accordance with this guideline，especially facing new requirements at key points such as reference listed drug selection，dissolution behavior evaluation，and labile iron control.

Cross-border medical tourism channel service providers：This includes travel agencies engaged in packaged “medical + tourism” services，international health service platforms，and local operators of overseas wellness destinations. In processes such as procurement decisions for supporting pharmaceuticals，supplier qualification audits，and updates to clinical use instructions，they need to simultaneously monitor the potential knock-on effects of this guideline on product registration status，labeling of indications in package inserts，and adverse reaction monitoring requirements.

Key Points Relevant Enterprises or Practitioners Should Focus On，and How to Respond at Present

Pay attention to subsequent official statements and the adoption of feedback

The current document is in the public comment stage，and the final version may adjust BE waiver conditions，the scope of reference preparation catalogs，or data requirements for medication use in special populations. Relevant enterprises are advised to continuously track announcements on the CDE official website，with particular attention to whether revised explanations or a timetable for the release of the official version will be issued before the end of the third quarter of 2026.

Review differences in registration pathways for existing export target markets

The degree of acceptance of BE data for iron sucrose injection varies across different countries/regions（such as Southeast Asia，the Middle East，and some Latin American countries）. Enterprises should compare the technical points of this guideline item by item against the current requirements of drug regulatory authorities in target markets（such as Saudi SFDA，Thailand FDA，and Brazil ANVISA），and identify key gaps requiring supplementary studies or resubmission of materials.

Distinguish policy signals from the practical pace of business implementation

This guideline is a technical reference document and does not have mandatory legal effect；its binding force depends on whether it is subsequently included in the supporting list of the Guidelines for Quality and Efficacy Consistency Evaluation of Chemical Generic Drugs，or whether it becomes a substantive threshold for overseas registration applications. At present，it is more appropriate to understand it as a signal of regulatory trends rather than an instructive basis that immediately triggers supply chain rectification.

Prepare contingency plans for key supply chain links in advance

For enterprises involving iron sucrose API suppliers，aseptic filling plants，and partner laboratories for stability studies，it is recommended to immediately check whether existing process parameters，batch record data，and dissolution curve databases meet the requirements in the guideline regarding batch representativeness，degradation product control，and exploratory analysis of in vitro-in vivo correlation（IVIVC），so as to reserve a response window for possible subsequent supplementary studies.

Editorial Viewpoint / Industry Observation

Observably, this guidance draft signals a tightening of technical expectations for intravenous iron products in cross-border health tourism contexts—not as an immediate compliance deadline, but as an early indicator of how regulatory alignment between pharmaceutical quality standards and integrated medical tourism service delivery is evolving. It reflects growing attention to the clinical accountability of drugs embedded in non-hospital travel-health models. From an industry perspective, it is better understood as a procedural calibration step rather than a market access barrier; its real impact will depend on whether and how it becomes referenced in bilateral recognition agreements or regional harmonization frameworks (e.g., ASEAN Common Technical Dossier requirements). Continuous monitoring remains essential—not because the rule is active now, but because its logic may extend to other IV micronutrient formulations used in similar settings.

Conclusion：The release of this draft guideline for comments indicates that the quality evaluation of key therapeutic drugs in foreign-related health tourism scenarios is gradually being incorporated into a more rigorous scientific and standardized track. At the current stage，it should not be overinterpreted as a mandatory access threshold；rather，it is more appropriately understood as a further clarification by the regulatory system of the responsibility boundaries across the full pharmaceutical chain in the integrated “cultural tourism + medical care” business model. Industry participants should follow policy developments with a prudent and pragmatic attitude，focusing on the registration adaptability and data completeness development of their own products in target markets.

Information source statement：
Main source：Official announcement of the Center for Drug Evaluation（CDE）of the National Medical Products Administration（published on May 29，2026）
Items requiring continuous observation：release timing of the official version，whether it will be included in the supporting list for consistency evaluation，and trends in citation or mutual recognition of this guideline by overseas regulatory authorities